Latest news with #Amaryl
Time of India
5 days ago
- Business
- Time of India
Emcure, Sanofi tie up for anti-diabetic range
New Delhi: Emcure Pharma and Sanofi India announced that they entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India, effective immediately. Emcure will exclusively distribute and promote the range of products, which include brands like Amaryl and Cetapin.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Emcure Pharma, Sanofi India shares edge higher; what's behind the move?
Emcure Pharmaceuticals share price today: Shares of pharma major Emcure Pharmaceuticals rose over 2 per cent to hit an intraday high of ₹1,394.8 on the National Stock Exchange (NSE) after the company announced a distribution and promotion partnership with Sanofi India on Wednesday. At 9:30 AM, the stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5. In comparison, the benchmark NSE Nifty50 index was trading marginally down by 15.5 points at 25,196.55 levels. The total market capitalisation of Emcure Pharmaceuticals stood at ₹26,216.58 crore. Shares of Sanofi India also gained around 1.5 per cent to hit an intraday high of ₹5,975. At the time of writing, the stock was quoting 1.2 per cent higher at ₹5,956.5. Emcure Pharmaceuticals and Sanofi India have entered a distribution and promotion partnership aimed at expanding access to Sanofi's oral anti-diabetic (OAD) products across India. Effective immediately, Emcume will exclusively distribute and promote Sanofi's OAD range of products, including established brands like Amaryl and Cetapin. However, Sanofi India will continue to own and manufacture these brands across Sanofi's plants in India and internationally. "Emcure will leverage its strengths to engage healthcare professionals and expand the reach of these therapeutic solutions for patients who need them across all of India," the company said in an exchange filing. "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country,' said Satish Mehta, chief executive officer and managing director at Emcure Pharmaceuticals. About Emcure Pharma Headquartered in Pune, Emcure Pharmaceuticals is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 12th largest pharma company in India in terms of domestic sales for MAT June 2024. The company has a presence in more than 70 countries globally, including Europe and Canada.
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Emcure enters distribution agreement with Sanofi for diabetes drugs
Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. Sanket Koul New Delhi Pune-based Emcure Pharmaceuticals on Wednesday announced an exclusive distribution and promotion agreement with Sanofi India (SIL) for its oral anti-diabetic (OAD) products in India. Under the agreement, SIL will continue to own and manufacture the brands across its plants in India and internationally, while Emcure will exclusively distribute and promote SIL's OAD range, which includes well-established brands such as Amaryl and Cetapin. There will be no employee transition from SIL to Emcure as part of this arrangement, the Pune-based drugmaker said in a regulatory filing to the exchanges. Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. 'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' he added. Over 100 million Indians are currently living with type 2 diabetes and its associated complications, according to a study by the Indian Council of Medical Research–INDIAB (India Diabetes). 'Of these, more than 60 per cent are living with uncontrolled blood sugar levels and are at higher risk of developing complications over time,' said Eric Mansion, general manager (pharma) for Southeast Asia and India at Sanofi. He added that with Emcure's wide and deeply penetrated presence across India, the company is confident of tapping the full growth potential of Amaryl and Cetapin. The announcement was made post market hours. On Wednesday, shares of Emcure Pharmaceuticals closed marginally higher by 0.22 per cent at Rs 1,363.85 apiece on the Bombay Stock Exchange (BSE).
Business Standard
6 days ago
- Business
- Business Standard
Emcure Pharmaceuticals signs exclusive agreement with Sanofi India
To distribute and promote Emcure's oral anti-diabetic (OAD) products in India Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl and Cetapin. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India. There will be no people transition from SIL to Emcure in this arrangement.
Time of India
6 days ago
- Business
- Time of India
Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India
Emcure Pharmaceuticals Ltd and Sanofi India Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India with immediate effect. Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement. Explore courses from Top Institutes in Select a Course Category Operations Management Data Analytics Finance Data Science Artificial Intelligence MBA Product Management PGDM Technology Project Management Healthcare Cybersecurity Public Policy Degree MCA Leadership Management CXO Others Digital Marketing healthcare others Design Thinking Data Science Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hörspezialisten verlieren Kunden: Dieses 89€-Gerät spricht sich herum Top Trending News Today Mehr erfahren Undo "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them," Emcure Pharmaceuticals CEO and MD Satish Mehta said. Further, he said, "This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country." Live Events Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, "With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them." The two companies said there would be no people transition from Sanofi India to Emcure under their distribution and promotion agreement.
